MSB - Most exciting 6 months, page-165

i think just on that 30% interim, my guess is that it goes something like this:

1. 25/06 - Mesoblast announces that we've reached 90 patients with 30 days assessment, and have submitted for review
2. Early July - Independent review
3. Mid-late July - FDA approval

But, prior to #3, they need to fit in approval of Ryoncil somewhere, as this is their easiest path to tick a lot of boxes.

• We approved a product (Ryoncil) that have followed FDA processes, rules and guidelines
• We are now approve an extension of Ryoncil called Rem-L for Covid-19 ARDS treatment

Neat and ticks off all of the FDA steps.
Mesoblast gets a huge MOAT and hard for other companies to come into ARDS any time soon

How can this be anything, but HODL